Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental vitiligo, with familiar safety.
|Articles|February 2, 2017
2016 Year in Review: University of Michigan V-BID Center
Author(s)VBID Center
The University of Michigan Center for Value-Based Insurance Design (V-BID) celebrated significant initiative milestones in 2016.
Advertisement
Last year was a big year for value-based insurance design (VBID) and the University of Michigan Center for Value-Based Insurance Design celebrated significant initiative milestones in 2016. From the
View the
Advertisement
Related to this article
A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.
After Pennsylvania began rewarding Medicaid managed care plans for increasing well-child visits among Black infants, rates did not change significantly overall but varied by region.
Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.
A case report describes the first KRAS::ETNK1 fusion in MDS/MPN with eosinophilia; the fusion disappeared when disease relapsed as AML after transplant.
Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.
GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non–drug care up front.
Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5